Opinion|Videos|July 10, 2024
The Role of PSA Doubling Time in Risk Assessment
Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients.
Advertisement
Episodes in this series
- Dr. Efstathiou asks Dr. Freedland: In evaluating non-metastatic CSPC cases, what role does PSA doubling time play in your risk assessment?
- At what PSA doubling time thresholds do treatment recommendations change?
- How reliable is PSA doubling as a biomarker versus imaging or other tests?
Advertisement
Related to this article
The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualizing ARPI-based therapy in advanced prostate cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
OS Wins, New Approvals, and Practice-Changing Data: Breaking Down the Biggest NSCLC News From ASCO 2026
2
FDA Approves Rituximab Biosimilar for Hematologic Malignancies
3
Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC
4
Phase 1 Data Set the Stage for Further Exploration of Cevostamab in R/R Myeloma
5